Skip to main content
Duke University Libraries
Search 
  •   DukeSpace
  • Duke Scholarly Works
  • Search
  •   DukeSpace
  • Duke Scholarly Works
  • Search
    • Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Search

    Show Advanced FiltersHide Advanced Filters

    Filters

    Use filters to refine the search results.

    Now showing items 1-5 of 5

    • Sort Options:
    • Relevance
    • Title Asc
    • Title Desc
    • Issue Date Asc
    • Issue Date Desc
    • Results Per Page:
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
    Thumbnail

    Does generic entry always increase consumer welfare? 

    Grabowski, Henry G; Guha, R; Ivanova, Z; Lewis, Tracy; Salgado, M; Woodhouse, S (Food Drug Law J, 2012)
    This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into ...
    Thumbnail

    Entry and competition in generic biologics 

    Grabowski, Henry G; Ridley, David Blaine; Schulman, Kevin Alan (Managerial and Decision Economics, 2007-06-01)
    Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In ...
    Thumbnail

    Encouraging innovative treatment of neglected diseases through priority review vouchers 

    Grabowski, Henry G; Moe, Jeffrey L; Ridley, David Blaine (Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01)
    Thumbnail

    Spending on postapproval drug safety. 

    Grabowski, Henry G; Kramer, JM; Ridley, David Blaine; Schulman, Kevin Alan; Tilson, HH (Health Aff (Millwood), 2006-03)
    Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...
    Thumbnail

    Developing drugs for developing countries. 

    Grabowski, Henry G; Moe, Jeffrey L; Ridley, David Blaine (Health Aff (Millwood), 2006-03)
    Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments ...
     

     

    Browse

    All of DukeSpaceCommunities & CollectionsAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit DateThis CommunityAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit Date

    My Account

    LoginRegister

    Discover

    Author
    Grabowski, Henry G (5)
    Ridley, David Blaine (4)Moe, Jeffrey L (2)Schulman, Kevin Alan (2)Guha, R (1)Ivanova, Z (1)Kramer, JM (1)Lewis, Tracy (1)Salgado, M (1)Tilson, HH (1)... View MoreDate Issued2006 (2)2007 (1)2009 (1)2012 (1)TypeJournal article (4)Book section (1)SubjectHumans (3)United States (3)Drug Approval (2)Drug Industry (2)Anti-Infective Agents (1)Antiparasitic Agents (1)Consumer Advocacy (1)Costs and Cost Analysis (1)Developing Countries (1)Drug Costs (1)... View MoreAffiliation of Duke Author(s)Duke (5)Economics (5)
    Fuqua School of Business (5)
    Trinity College of Arts & Sciences (5)Duke Science & Society (4)Initiatives (4)Institutes and Provost's Academic Units (4)Global Health Institute (3)University Institutes and Centers (3)Clinical Science Departments (2)... View More